AI Summary & Key Takeaways
AI InsightObjectives: In breast cancer, pathological complete response (pCR) to neoadjuvant chemotherapy showed associa- tion with overall survival.
📌 3 Key Takeaways
Abstract
Objectives: In breast cancer, pathological complete response (pCR) to neoadjuvant chemotherapy showed associa- tion with overall survival. However, this relationship varied according to the tumor's receptor status and pathological features. In this paper we aimed to show response rates and predictive factors of pCR in luminal B HER2 negative breast cancer patients who received neoadjuvant chemotherapy (NC). Methods: We have searched the database retrospectively January 2015 and January 2020. Inclusion criteria for this study were women newly diagnosed, nonmetastatic ER positive, HER2 negative, PR positive or negative, ki67 ≥%20, T1-4 N1-3 breast cancer treated with NC followed by surgery and RT. All patients received regimen containing antracycline. Results: 82 patients met study criteria in our center. Invasive ductal carcinoma was the predominant tumor type (%77.5). pCR was achieved in only 12 patients (%14.6). In univariate analysis, factors associated with pCR were absence of LVI (p=0.003) and high grade of the tumor (p=0.002). Median OS and median EFS could not be reached. There was no death from patients with pCR. Conclusion: This study suggest that the presence of LVI is associated with poorer response, presence of high grade is associated with good response to NC in HER2 negative Luminal B breast cancer patients